JC Virus Vaccine

Background: JC virus is a polyomavirus that commonly infects humans. At least 80% of the population has been exposed to JC virus, but viral replication generally occurs only in connection with weakening of the immune system. The present inventors have shown that the DNA sequence of JC virus is present in the mucosa of normal human colons, adenomatous polyps of the colon, colorectal cancers, and colorectal cancer xenografts raised in nude mice. Additional results indicate that JC virus DNA can induce chromosomal instability in vitro, and it is proposed that JC virus is a key event in triggering the mechanisms involved in tumor development. Moreover, JC virus DNA can be detected in the DNA of cancers of the esophagus, stomach and pancreas.

Description of Present Technology: There is no present technology to prevent gastrointestinal cancers. The closest similar concept is immunization against human papillomavirus (HPV) to prevent cervical cancer.

Objective: An effective JC virus vaccination will be developed to prevent gastrointestinal cancers. The inventors have demonstrated that the JC Virus is present in colorectal tumors. The novel concept is that the prevention of JC virus infection through immunization will prevent gastrointestinal.

We are seeking an exclusive corporate partner, committed to vaccine research in the area of gastrointestinal cancers to partner with for the clinical development and marketing of the vaccine.

Contact

Office of Tech Transfer

3310 Live Oak, Suite 501

Dallas, TX 75204

214.820.2687

BRItechtransfer@baylorhealth.edu